非阿片类止痛贴市场（按技术、应用、产品类型、最终用户、分销管道和药物类型）—2025-2032 年全球预测

预计到 2032 年非鸦片类止痛贴市场规模将成长至 21.4046 亿美元，复合年增长率为 13.25%。

主要市场统计数据
基准年2024年	7.9097亿美元
预计2025年	8.9706亿美元
预测年份：2032年	2,140,​​460,000美元
复合年增长率（%）	13.25%

执行介绍强调了非阿片类经皮止痛贴生态系统的临床需求、技术进步和策略要点

非阿片类止痛贴片领域正随着医药创新、先进材料科学和不断发展的临床实践的交汇而日益成熟。随着临床医生和患者寻求能够同时缓解急性和慢性疼痛途径的局部、鸦片类药物替代疗法，新型经皮系统正日益受到青睐。与传统的外用製剂相比，黏合剂化学、微加工技术和微创给药机制的同步进步，使得药物的生物有效性得以提高，疗效也更加稳定。

临床医师越来越重视那些具有可预测药物动力学、降低全身暴露量并适应现有治疗途径的产品。同时，製造商正在开发以患者为中心的产品，包括可穿戴性、皮肤耐受性和诊所外给药的便利性。因此，策略决策取决于整合临床证据、监管透明度和供应链韧性。本执行摘要的其余部分整合了这些因素，重点介绍了关键的技术变革、监管和贸易逆风、细分市场主导的商业机会，以及行业领导者可以采用的实用建议，以便将技术前景转化为商业性和临床影响。

深入综合技术、临床和给药创新的融合，重塑非鸦片类经皮镇痛策略和供应商的采用

非鸦片类止痛贴片领域正在经历一场变革，这得益于给药技术、黏合剂科学和实证临床应用的融合发展。微针阵列（包括可溶解和固态形式）正在从学术原型走向可扩展生产，从而能够经经皮获取先前受皮肤渗透性限制的分子。同时，包括丙烯酸树脂、水凝胶和硅酮在内的黏合剂平台也在不断发展，以平衡药物相容性和患者舒适度，从而提高急性和慢性护理环境中的依从性。

同时，产品设计在基质、微针和储库配置方面呈现差异化，凝胶和液体储库配方日益受到关注。这些配方可实现更精确的剂量控制和缓释性特性，最终减少对全身性止痛药的需求。随着医院、诊所和居家照护机构将贴片整合到多种疼痛治疗方案中，临床路径也不断调整，不仅关注关节炎和神经病变疼痛等慢性疾病，还关注术后和运动相关的急性疼痛。此外，从依从性感测器到与电子健康记录的集成，数位化能正在提升监测疗效和支持报销对话的潜力。这些转变共同创造了一个更加差异化的竞争格局，其中临床检验和生产规模是关键驱动因素。

基于证据的分析：2025 年美国关税将如何影响经皮药物供应链的弹性、筹资策略和製造决策

2025年生效的美国关税措施，对医疗设备供应链、原料采购以及支持经皮贴片生产的零件进口造成了显着的摩擦。影响聚合物、黏合剂前驱物、电子感测器模组和专用微针製造设备的关税调整，迫使製造商重新评估其供应商关係和生产布局。为此，一些公司正在优先考虑关键投入的近岸外包，寻找替代材料来源，并加速垂直整合，以缓衝成本波动和前置作业时间风险。

关税不仅影响直接投入成本，还影响商业决策，例如库存策略和与目标商标产品製造商的合约条款。采购团队越来越多地与供应商协商长期合同，以稳定单位成本并遵守生产计划。监管备案和品管流程也受到影响，因为製造商在供应商变更时检验零件。此外，关税也透过改变资本配置间接影响创新时间表。考虑投资自动化、无尘室扩建和微针工具的公司现在正在将贸易政策纳入其资本计划。最终，关税环境凸显了在将新的非阿片类药物贴片技术推向市场时，供应链敏捷性、强大的供应商资格认证计划以及基于场景的成本模型的重要性。

将黏合剂化学、递送形式、临床指征、最终用户通路和药物有效载荷选择与开发和商业化路径联繫起来的细緻入微、细分主导的观点

细分洞察揭示了产品开发、监管策略和上市计划如何与多样化的患者需求和医疗保健环境相协调。在考虑黏合剂技术时，丙烯酸、水凝胶和硅胶黏合剂在皮肤耐受性、药物相容性和佩戴时间性能方面的区别至关重要，每种黏合剂都需要独特的生物相容性测试和供应链考虑。急性病例着重于术后疼痛和运动伤害，优先考虑快速给药和易于清除；而关节炎和神经病变疼痛等慢性治疗则强调持续给药、长期耐受性和患者依从性。

依产品类型（基质贴片、微针贴片和储药贴片）进行区分意味着不同的开发重点。微针选项分为溶解式和固态微针方法，这会带来与生物降解和设备分类相关的监管和製造限制。同时，具有凝胶或液体储药器结构的储药贴片变体需要严格控制药物稳定性和释放动力学。医院进一步分为私人医院和公立医院，诊所、居家照护和医院的最终用户细分为培训、库存管理和报销途径。最后，医院药局、线上药局和零售药局（零售药局细分为 OTC 和处方笺通路）之间的分销动态会影响标籤、包装和病患教育策略。考虑辣椒素、Lidocaine和非类固醇消炎剂化合物的药物有效载荷，进一步完善临床定位。

详细的区域评估，解释重点地区的法律规范、付款人动态和临床基础设施如何影响采用和商业化策略

区域动态决定了非鸦片类贴片市场的投资重点、监管格局和策略伙伴关係。在美洲，完善的临床基础设施和新型疼痛管理模式的高采用率，为医院和诊所的采用提供了肥沃的土壤，但报销谈判和采购流程需要提供量身定制的证据包，以证明其相对有效性和实际效用。该地区的供应链注重可追溯性和法规遵循性，製造商通常将生产和最终组装设在靠近终端市场的地方，以控制前置作业时间和关税。

欧洲、中东和非洲呈现出异质的法规环境，每个国家都有独特的临床要求和报销框架，需要灵活的监管策略和区域付款人的参与。与医院网路的合作试点计画可以加速卓越中心的采用，而与区域经销商的伙伴关係可以帮助应对复杂的进口和采购法规。亚太地区既包括拥有成熟临床生态系统的已开发市场，也包括医疗保健预算有限的新兴市场。在该地区的高所得经济体中，创新的采用由临床领导者和私人付款人推动，而在新兴市场，製造商必须优化成本、供应链物流和简化培训才能实现有意义的采用。在所有地区，监管清晰度、临床医生教育和已证实的患者结果对于扩大非阿片类药物贴片的使用仍然至关重要。

竞争格局的策略概况揭示了智慧财产权、伙伴关係、製造能力和证据生成将如何决定非经皮治疗领域的领导地位

非鸦片类止痛贴片领域的竞争格局特点是，成熟的製药和设备公司正在拓展经皮解决方案，而专业的新兴企业则专注于微针平台和黏合剂创新。领先的公司正在优先考虑整合策略，将专有的给药技术与强大的临床证据包和可扩展的生产能力相结合。与微针几何形状、储库密封方法和黏合剂化学相关的智慧财产权组合对于保持差异化并在许可和伙伴关係谈判中占据有利地位至关重要。

医疗设备製造商、合约开发与受託製造厂商以及临床研究网络之间的策略联盟正变得越来越普遍，以加快临床开发速度并管理资本密集度。同时，掌握关键零件（例如专用医用聚合物或微加工工具）的公司可以在与供应商的谈判中获得优势，并影响行业标准。新参与企业往往专注于利基临床适应症或独特的交付模式，以建立Proofpoint。在这两个领域，成功的关键在于协调监管策略、扩大生产规模和上市后监测，以建立临床医生的信任并支持长期应用。

製造商和相关人员可采取的策略要务是加速采用、加强供应链，并将临床证据与付款人参与和商业执行结合起来

产业领导者应制定综合蓝图，在科学差异化与实际可行的上市时间之间取得平衡。例如，针对长期慢性适应症，选择水凝胶和硅胶黏合剂，针对短期急性适应症，选择丙烯酸黏合剂。投资能够产生比较有效性和患者报告结果数据的临床项目，并与大型外科中心和运动医学诊所进行早期合作，以产生令人信服的真实世界证据。

从营运角度来看，我们将实现关键投入品供应链多元化，并提升二级供应商的资质，以降低关税和地缘政治风险。我们将考虑近岸製造和区域合作，以缩短前置作业时间并简化监管申报流程。我们将建造灵活的生产线，能够容纳基质、储存库和微针製剂，从而涵盖多种治疗领域。我们将利用健康经济模型和依从性数据，儘早与付款人互动，以支援覆盖决策，并设计能够反映预期分销管道（例如医院药房、线上药房或需要非处方药和处方笺标籤的零售管道）的包装和标籤策略。最后，我们将建立上市后监测通讯协定和数位依从性工具，以捕捉能够强化临床医师和付款人价值提案的成果。

一种透明且严格的混合方法研究途径，将主要临床和供应链访谈与监管、专利和产品文件的技术审查相结合

本执行摘要所依据的初步研究采用了混合方法，强调临床输入和严格的技术审查。初步研究包括对疼痛专家、采购主管、法规事务专业人员和製造专家的结构化访谈，以了解实际限制、应用驱动因素和采购行为。这些见解与同行评审的临床文献、公开的监管备案文件、产品标籤和专利披露进行了交叉引用，以确保关于粘合剂化学、微针技术和储液器构造的技术声明基于检验的公共来源。

营运分析涵盖了供应商图谱、组件认证途径以及透过与製造外包和品质负责人访谈而得出的生产规模考量。透过分析关税表、与聚合物和设备组件相关的关税分类，以及对已调整筹资策略的公司案例研究，评估了贸易政策的影响。在整个研究过程中，我们运用了品管措施，包括受访者检验、资讯来源三角测量和调查方法透明度，以最大限度地减少偏差并提高结论的可靠性。由此得出的见解旨在为策略规划、临床专案设计和商业性执行提供信息，而无需依赖专有的市场规模假设。

将非经皮技术能力、临床证据需求和营运准备与实际采用途径联繫起来的明确结论

摘要，非鸦片类止痛贴片代表极具吸引力的治疗和商业机会，需要兼顾技术创新、临床效用和营运弹性。微针技术、多样化黏合剂化学和储存库结构的进步正在扩大能够有效治疗急性和慢性疼痛的经皮贴片的范围。成功的市场准入取决于建立可靠的临床证据，打造灵活且具有韧性的供应链以适应贸易政策和投入成本的波动，并以清晰的价值提案赢得付款人和医疗保健系统的青睐。

展望未来，相关人员产品设计与特定临床路径结合、投资可扩展的生产和品质系统、并在分销管道中建立策略伙伴关係关係的利益相关者，将最有能力将创新转化为持续的临床应用。阿片类药物减量疼痛管理的集体行动提供了令人鼓舞的临床背景，但要将其潜力转化为日常实践，需要在监管、商业和营运领域严格执行。本报告中的见解旨在透过实用的实证建议来指导这些决策。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 微针阵列的整合增强了非鸦片类镇痛药的经皮输送
• 开发生物黏附聚合物基质以延长非鸦片类贴片的配戴时间
• 奈米载体製剂的出现提高了镇痛药的稳定性和皮肤渗透性
• 在止痛贴片中采用智慧感测器回馈，实现个人化剂量和监测
• 监管奖励将加快 FDA 对 CBD 和植物止痛贴的核准流程
• 製药和医疗科技公司结成策略联盟，创新穿戴式止痛贴片平台
• 转向可生物降解、环保的贴片背衬，减少一次性塑胶废弃物

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 非阿片类止痛贴市场（按技术）

• 丙烯酸黏合剂
• 水凝胶黏合剂
• 硅胶黏合剂

9. 非鸦片类止痛贴市场（依应用）

• 急性疼痛
  • 术后疼痛
  • 运动伤害引起的疼痛
• 慢性疼痛
  • 关节炎
  • 神经病变疼痛

10. 非阿片类止痛贴市场（依产品类型）

• 矩阵补丁
• 微针贴片
  • 可溶解微针
  • 实心微针
• 水库斑块
  • 凝胶储液器
  • 储液罐

第 11 章非鸦片类止痛贴市场（依最终用户划分）

• 诊所
• 居家护理
• 医院
  • 私立医院
  • 公立医院

12. 非鸦片类止痛贴市场（依通路）

• 医院药房
• 网路药局
• 零售药局
  • 在商店
  • 处方笺

13. 非鸦片类止痛贴市场（依药物类型）

• 辣椒素
• Lidocaine
• 非类固醇消炎剂

14. 非鸦片类止痛贴市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第 15 章非鸦片类止痛贴市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

16. 非鸦片类止痛贴市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Hisamitsu Pharmaceutical Co., Inc.
  • Endo International plc
  • Johnson & Johnson
  • Viatris Inc.
  • Perrigo Company plc
  • Haw Par Corporation Limited
  • Upsher-Smith Laboratories, Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.

The Non-opioid Pain Patches Market is projected to grow by USD 2,140.46 million at a CAGR of 13.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 790.97 million
Estimated Year [2025]	USD 897.06 million
Forecast Year [2032]	USD 2,140.46 million
CAGR (%)	13.25%

An executive introduction that clarifies clinical needs, technological advancements, and strategic imperatives shaping the non-opioid transdermal pain patch ecosystem

The non-opioid pain patch landscape is maturing at the intersection of pharmaceutical innovation, advanced materials science, and evolving clinical practice. Novel transdermal systems are gaining traction as clinicians and patients seek localized, opioid-sparing alternatives that address both acute and chronic pain pathways. Concurrent advances in adhesive chemistries, microfabrication, and minimally invasive delivery mechanisms are enabling improved drug bioavailability and more consistent therapeutic profiles compared with older topical formats.

Clinicians are increasingly prioritizing products that demonstrate predictable pharmacokinetics, lower systemic exposure, and compatibility with existing care pathways. Meanwhile, manufacturers are aligning product development with patient-centered design considerations such as wearability, skin tolerability, and ease of administration outside clinical settings. As a result, strategic decisions now hinge on integrating clinical evidence, regulatory clarity, and supply chain resilience. The remainder of this executive summary synthesizes these forces, highlighting the pivotal technology shifts, regulatory and trade headwinds, segmentation-driven opportunities, and pragmatic recommendations that industry leaders can deploy to translate technical promise into commercial and clinical impact.

A detailed synthesis of the converging technology, clinical, and delivery innovations that are reshaping non-opioid transdermal analgesic strategies and provider adoption

The landscape for non-opioid pain patches is undergoing transformative shifts driven by converging advances in delivery technologies, adhesive science, and evidence-based clinical adoption. Microneedle arrays, including dissolvable and solid variants, are moving beyond academic prototypes toward scalable manufacturing, enabling transdermal access to molecules previously restricted by skin permeability. At the same time, adhesive platforms such as acrylic, hydrogel, and silicone formulations are evolving to balance drug compatibility with patient comfort, thereby improving adherence in both acute and chronic care settings.

Concurrently, product design is differentiating across matrix, microneedle, and reservoir configurations with attention to reservoir formulations in both gel and liquid forms. These form factors allow more precise dosing control and prolonged release profiles, which in turn reduce the need for systemic analgesics. Clinical pathways are adapting as hospitals, clinics, and home-care providers integrate patches into multimodal pain protocols, emphasizing postoperative and sports-related acute pain as well as chronic indications such as arthritis and neuropathic pain. In addition, digital enablement-ranging from adherence sensors to integration with electronic health records-amplifies the potential to monitor outcomes and support reimbursement conversations. Taken together, these shifts create a more differentiated competitive landscape where clinical validation and manufacturing scale are decisive.

An evidence-based analysis of how 2025 United States tariff measures are affecting supply chain resilience, procurement strategies, and manufacturing decisions for transdermal therapies

United States tariff policy enacted in 2025 has introduced measurable friction across medical device supply chains, raw-material sourcing, and component imports that underpin transdermal patch manufacturing. Tariff adjustments affecting polymers, adhesive precursors, electronic sensor modules, and specialized microneedle production equipment have prompted manufacturers to reassess supplier relationships and production footprints. In response, some firms are prioritizing nearshoring of critical inputs, qualifying alternative material sources, and accelerating vertical integration to buffer cost variability and lead-time risk.

Beyond direct input cost implications, tariffs have influenced commercial decisions such as inventory strategies and contract terms with original equipment manufacturers. Procurement teams are increasingly negotiating long-term supplier agreements to stabilize unit costs and protect production schedules. Regulatory filings and quality control processes have also been affected, as manufacturers revalidate components when suppliers change. Moreover, tariffs have had an indirect effect on innovation timelines by altering capital allocation; companies weighing investments in automation, cleanroom expansion, or microneedle tooling now factor trade policy into capital planning. Ultimately, the tariff environment underscores the importance of supply chain agility, robust supplier qualification programs, and scenario-based cost modeling when bringing new non-opioid patch technologies to market.

A nuanced segmentation-driven perspective that links adhesive chemistry, delivery formats, clinical indications, end-user channels, and drug payload choices to development and commercialization pathways

Segmentation insights reveal how product development, regulatory strategy, and go-to-market planning must align with diverse patient needs and care settings. When considering adhesive technology, distinctions among Acrylic Adhesive, Hydrogel Adhesive, and Silicone Adhesive matter for skin tolerability, drug compatibility, and wear-time performance, each demanding unique biocompatibility testing and supply chain considerations. Application segmentation separates acute and chronic pain pathways; acute use cases emphasize postoperative pain and sports injury pain where rapid onset and ease of removal are priorities, whereas chronic care targets such as arthritis and neuropathic pain focus on sustained delivery, long-term tolerability, and patient adherence.

Product type differentiation between Matrix Patch, Microneedle Patch, and Reservoir Patch drives divergent development priorities. Microneedle options-differentiated into Dissolvable Microneedle and Solid Microneedle approaches-introduce distinct regulatory and manufacturing constraints related to biodegradation and device classification, while Reservoir Patch variants with Gel Reservoir or Liquid Reservoir architectures require rigorous control of drug stability and release kinetics. End-user segmentation across Clinics, Home Care, and Hospitals, with Hospitals further categorized into Private Hospitals and Public Hospitals, informs training, inventory management, and reimbursement pathways. Finally, distribution dynamics across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, with Retail Pharmacy subdivided into Over-The-Counter and Prescription channels, influence labeling, packaging, and patient education strategies. Drug payload considerations among Capsaicin, Lidocaine, and Nonsteroidal Anti-Inflammatory Drug compounds further refine clinical positioning, as each molecule has distinct safety, contraindication, and monitoring profiles that shape labeling and commercialization tactics.

An in-depth regional assessment explaining how differing regulatory frameworks, payer dynamics, and clinical infrastructures in key geographies influence adoption and commercialization strategies

Regional dynamics are shaping investment priorities, regulatory pathways, and strategic partnerships across the non-opioid patch landscape. In the Americas, established clinical infrastructure and high adoption rates of novel analgesic modalities create fertile ground for hospital and clinic uptake, yet reimbursement negotiations and procurement processes require tailored evidence packages that demonstrate comparative effectiveness and real-world utility. Supply chain considerations in this region emphasize traceability and regulatory compliance, with manufacturers often locating production or final assembly closer to end markets to manage lead times and tariff exposure.

Europe, Middle East & Africa presents a heterogeneous regulatory environment where country-specific clinical requirements and reimbursement frameworks necessitate flexible regulatory strategies and localized payer engagement. Collaborative pilot programs with hospital networks can accelerate adoption in centers of excellence, while partnerships with regional distributors help navigate complex import and procurement rules. Asia-Pacific encompasses both advanced markets with sophisticated clinical ecosystems and emerging markets with constrained healthcare budgets. In high-income economies within the region, innovation adoption is driven by clinical leadership and private payers, whereas in emerging markets, manufacturers must optimize cost, supply chain logistics, and simplified training to achieve meaningful penetration. Across all regions, regulatory clarity, clinician education, and demonstrable patient outcomes remain vital to scaling non-opioid patch use.

A strategic profile of the competitive landscape highlighting how IP, partnerships, manufacturing capacity, and evidence generation determine leadership in the non-opioid transdermal sector

Competitive dynamics within the non-opioid pain patch sector are characterized by a mix of established pharmaceutical and device firms expanding into transdermal solutions, alongside specialized startups focusing on microneedle platforms and adhesive innovation. Leading organizations are prioritizing integrated strategies that combine proprietary delivery technologies with robust clinical evidence packages and scalable manufacturing capabilities. Intellectual property portfolios around microneedle geometries, reservoir sealing methods, and adhesive chemistries are central to maintaining differentiation and command licensing or partnership negotiations.

Strategic collaborations between device manufacturers, contract development and manufacturing organizations, and clinical research networks are increasingly common as they accelerate time to clinic while managing capital intensity. In parallel, companies that control key components-such as specialized medical-grade polymers and microfabrication tooling-gain leverage in supplier negotiations and can influence industry standards. New entrants tend to focus on niche clinical indications or unique delivery modalities to establish proof points, whereas incumbent players deploy broader commercialization networks and payer engagement expertise. Across the spectrum, success hinges on harmonizing regulatory strategy, manufacturing scale-up, and post-market surveillance to build clinician confidence and support long-term adoption.

Actionable strategic imperatives for manufacturers and stakeholders to accelerate adoption, strengthen supply chains, and align clinical evidence with payer engagement and commercialization execution

Industry leaders should pursue an integrated roadmap that balances scientific differentiation with pragmatic go-to-market execution. Prioritize development of adhesive and delivery platforms that match the intended clinical use; for example, select hydrogel or silicone adhesives for long-wear chronic indications while favoring acrylic systems for short-duration acute applications. Invest in clinical programs that generate comparative effectiveness and patient-reported outcome data, with early collaborations in high-volume surgical centers and sports medicine clinics to create compelling real-world evidence.

From an operational perspective, diversify supply chains for critical inputs and qualify secondary suppliers to mitigate tariff and geopolitical risks. Explore nearshore manufacturing or regional partnerships to reduce lead times and simplify regulatory filings. Build flexible production lines that can accommodate matrix, reservoir, and microneedle formats to capture multiple therapeutic niches. Engage payers early with health economic models and adherence data to support coverage decisions, and design packaging and labeling strategies that reflect the intended distribution channel-whether hospital pharmacy, online pharmacy, or retail channels requiring OTC or prescription classification. Finally, establish post-market surveillance protocols and digital adherence tools to collect outcomes that reinforce value propositions for clinicians and payers alike.

A transparent and rigorous mixed-methods research approach combining primary clinical and supply chain interviews with technical review of regulatory, patent, and product documentation

The research synthesis underpinning this executive summary used a mixed-methods approach that emphasizes primary clinical input and rigorous technical review. Primary research included structured interviews with pain specialists, procurement leaders, regulatory affairs professionals, and manufacturing experts to capture practical constraints, adoption drivers, and procurement behaviors. These insights were triangulated with a targeted review of peer-reviewed clinical literature, public regulatory filings, product labeling, and patent disclosures to ensure technical assertions about adhesive chemistries, microneedle technologies, and reservoir architectures are grounded in verifiable public materials.

Operational analyses incorporated supplier mapping, component qualification pathways, and manufacturing scale considerations derived from interviews with contract manufacturing organizations and quality leaders. Trade policy impacts were evaluated through analysis of tariff schedules, customs classifications relevant to polymer and device components, and case studies of firms that adjusted sourcing strategies. Throughout the research process, quality control measures such as respondent verification, source triangulation, and methodological transparency were applied to minimize bias and enhance the reliability of conclusions. The resulting insights are intended to inform strategic planning, clinical program design, and commercial execution without relying on proprietary market-sizing assumptions.

A decisive conclusion that ties technological capabilities, clinical evidence needs, and operational readiness to practical adoption pathways for non-opioid transdermal therapies

In summary, non-opioid pain patches represent a compelling therapeutic and commercial opportunity contingent on harmonizing technological innovation with clinical utility and operational resilience. Advances in microneedle technologies, diverse adhesive chemistries, and reservoir architectures are expanding the range of transdermal solutions that can effectively treat both acute and chronic pain indications. Successful market entry depends on generating robust clinical evidence, building flexible and resilient supply chains that can respond to trade-policy and input-cost volatility, and engaging payers and health systems with clear value propositions.

Going forward, stakeholders that align product design with specific clinical pathways, invest in scalable manufacturing and quality systems, and nurture strategic partnerships across distribution channels will be best positioned to translate technical innovation into sustained clinical adoption. The collective movement toward opioid-sparing pain management provides an encouraging clinical backdrop, but converting that potential into routine practice requires disciplined execution across regulatory, commercial, and operational domains. This report's insights aim to guide those decisions with practical, evidence-informed recommendations.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of microneedle arrays to enhance transdermal delivery of non-opioid analgesics
• 5.2. Development of bioadhesive polymer matrices to extend non-opioid patch wear duration
• 5.3. Emergence of nanocarrier formulations improving stability and skin permeation of analgesics
• 5.4. Adoption of smart sensor feedback in pain patches for personalized dosing and monitoring
• 5.5. Regulatory incentives accelerating FDA approval pathways for CBD and botanical pain patches
• 5.6. Strategic collaborations between pharma and medtech firms to innovate wearable pain patch platforms
• 5.7. Shift towards biodegradable and eco-friendly patch backings to reduce single-use plastic waste

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-opioid Pain Patches Market, by Technology

• 8.1. Acrylic Adhesive
• 8.2. Hydrogel Adhesive
• 8.3. Silicone Adhesive

9. Non-opioid Pain Patches Market, by Application

• 9.1. Acute Pain
  • 9.1.1. Postoperative Pain
  • 9.1.2. Sports Injury Pain
• 9.2. Chronic Pain
  • 9.2.1. Arthritis
  • 9.2.2. Neuropathic Pain

10. Non-opioid Pain Patches Market, by Product Type

• 10.1. Matrix Patch
• 10.2. Microneedle Patch
  • 10.2.1. Dissolvable Microneedle
  • 10.2.2. Solid Microneedle
• 10.3. Reservoir Patch
  • 10.3.1. Gel Reservoir
  • 10.3.2. Liquid Reservoir

11. Non-opioid Pain Patches Market, by End User

• 11.1. Clinics
• 11.2. Home Care
• 11.3. Hospitals
  • 11.3.1. Private Hospitals
  • 11.3.2. Public Hospitals

12. Non-opioid Pain Patches Market, by Distribution Channel

• 12.1. Hospital Pharmacy
• 12.2. Online Pharmacy
• 12.3. Retail Pharmacy
  • 12.3.1. Over-The-Counter
  • 12.3.2. Prescription

13. Non-opioid Pain Patches Market, by Drug Type

• 13.1. Capsaicin
• 13.2. Lidocaine
• 13.3. Nonsteroidal Anti-Inflammatory Drug

14. Non-opioid Pain Patches Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Non-opioid Pain Patches Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Non-opioid Pain Patches Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Hisamitsu Pharmaceutical Co., Inc.
  • 17.3.2. Endo International plc
  • 17.3.3. Johnson & Johnson
  • 17.3.4. Viatris Inc.
  • 17.3.5. Perrigo Company plc
  • 17.3.6. Haw Par Corporation Limited
  • 17.3.7. Upsher-Smith Laboratories, Inc.
  • 17.3.8. Novartis AG
  • 17.3.9. Teva Pharmaceutical Industries Ltd.
  • 17.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. NON-OPIOID PAIN PATCHES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. NON-OPIOID PAIN PATCHES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. NON-OPIOID PAIN PATCHES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 207. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 208. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 209. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 210. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 211. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 223. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 224. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 227. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 228. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 234. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
• TABLE 240. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 242. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2024 (USD MILLION)
• TABLE 244. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2025-2032 (USD MILLION)
• TABLE 245. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2024 (USD MILLION)
• TABLE 246. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 251. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 252. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 253. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 254. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 255. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 256. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 260. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 261. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 262. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
• TABLE 264. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
• TABLE 265. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
• TABLE 266. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
• TABLE 267. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 268. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 269. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2024 (USD MILLION)
• TABLE 270. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2025-2032 (USD MILLION)
• TABLE 271. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2024 (USD MILLION)
• TABLE 272. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2025-2032 (USD MILLION)
• TABLE 273. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 274. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 275. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 276. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 277. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 278. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 279. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 280. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 281. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 282. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
• TABLE 293. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 294. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 295. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2024 (USD MILLION)
• TABLE 296. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2025-2032 (USD MILLION)
• TABLE 297. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2024 (USD MILLION)
• TABLE 298. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2025-2032 (USD MILLION)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)

TABLE